Nomura Asset Management Co. Ltd. Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Nomura Asset Management Co. Ltd. decreased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 338,525 shares of the medical research company's stock after selling 1,732 shares during the quarter. Nomura Asset Management Co. Ltd. owned about 0.06% of Amgen worth $88,233,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of AMGN. Norges Bank acquired a new position in Amgen in the 4th quarter valued at $1,541,991,000. Charles Schwab Investment Management Inc. increased its stake in shares of Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares during the period. Raymond James Financial Inc. purchased a new position in Amgen during the fourth quarter worth about $401,913,000. Van ECK Associates Corp lifted its position in Amgen by 263.8% in the fourth quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock valued at $270,699,000 after purchasing an additional 753,147 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in Amgen by 40.7% in the 4th quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company's stock valued at $609,526,000 after purchasing an additional 676,598 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 in the last quarter. 0.69% of the stock is owned by insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Piper Sandler increased their target price on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Piper Sandler Companies restated an "overweight" rating and set a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Wells Fargo & Company reiterated an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Citigroup reissued a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Truist Financial dropped their target price on shares of Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $314.04.

Amgen Trading Down 0.6 %

Shares of Amgen stock traded down $1.97 during trading hours on Tuesday, reaching $309.58. 689,374 shares of the company's stock were exchanged, compared to its average volume of 2,695,776. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a fifty day moving average of $301.87 and a 200-day moving average of $297.81. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The firm has a market capitalization of $166.31 billion, a price-to-earnings ratio of 41.00, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is currently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.